Marshall Wace, LLP Cullinan Oncology, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 1,053,764 shares of CGEM stock, worth $12.5 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,053,764
Previous 1,184,037
11.0%
Holding current value
$12.5 Million
Previous $20.6 Million
14.57%
% of portfolio
0.02%
Previous 0.03%
Shares
8 transactions
Others Institutions Holding CGEM
# of Institutions
146Shares Held
67.6MCall Options Held
612KPut Options Held
118K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$90.8 Million19.97% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$68.3 Million3.06% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$42.1 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$40.5 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$38.9 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $541M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...